EQUILLIUM, INC.

EQ NASDAQ
4.000
-0.050
-1.23%
Opening 09:30 08/21 EDT
Open
4.000
Prev Close
4.050
High
4.000
Low
4.000
Volume
213
Avg Vol (3M)
34.52K
52 Week High
19.69
52 Week Low
3.100
% Turnover
0.00%
Market Cap
66.79M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers EQUILLIUM, INC. EQ stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Equillium, Inc. is a biotechnology company. The Company develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. It plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.
MORE >

Recently

Name
Price
%Change